Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a pharmaceutical company currently trading near $1.95 and showing a strong 17.47% gain over the past week, held its 2025 Annual Meeting of Stockholders on Friday. According to a statement based on a recent SEC filing, shareholders approved all proposals presented at the meeting.
Amit Munshi and David Canner, Ph.D., were elected as Class II directors to the company’s board. Munshi received 56,789,636 votes in favor and 914,072 votes withheld, while Canner received 57,684,839 votes in favor and 18,869 votes withheld. Both directors will serve until the 2028 annual meeting or until a successor is duly elected and qualified.
Shareholders also ratified the appointment of CohnReznick LLP as Inhibikase Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received 61,078,342 votes in favor, 29,037 votes against, and 1,194 abstentions.
In addition, an amendment to the company’s 2020 Equity Incentive Plan was approved. The amendment includes an automatic “evergreen” provision and extends the term of the plan. This proposal received 46,263,058 votes in favor, 11,381,113 votes against, and 59,537 abstentions.
No other matters were submitted to a vote at the meeting. The information is based on a press release statement and details from the company’s SEC filing.
In other recent news, Ludwig Enterprises announced the appointment of Garth Lees-Rolfe as an independent director. This decision was made by the company’s board of directors and disclosed in a press release following a recent SEC filing. Mr. Lees-Rolfe, who brings over 19 years of experience in finance and strategic financial planning, will serve as a director until the expiration of his term or the election and qualification of a successor. Meanwhile, Inhibikase Therapeutics has appointed David McIntyre as its new Chief Financial Officer. Mr. McIntyre’s extensive experience in the life sciences sector, including roles at Anthos Therapeutics and HeartWare International, is expected to be a significant asset for Inhibikase. The company is advancing its lead product, IkT-001, for pulmonary arterial hypertension and preparing for a Phase 2b trial. Both companies have made these strategic appointments to strengthen their leadership teams and enhance their operational capabilities. These developments were reported through press releases and SEC filings, providing investors with insights into the companies’ recent strategic moves.
